ClinicalTrials.gov
ClinicalTrials.gov Menu

Primary Liver Cancer Cohort of South China

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03297255
Recruitment Status : Recruiting
First Posted : September 29, 2017
Last Update Posted : September 29, 2017
Sponsor:
Information provided by (Responsible Party):
Huilian Zhu, Sun Yat-sen University

Brief Summary:
This longitudinal observational cohort study was designed to investigate factors that influencing the occurrence and long-term survival of patients with primary liver cancer. Basic informations and detailed diagnosis informations (AJCC/TNM stage, MELD score, Child-Pugh score, and BCLC stage) were collected by professional doctors. Clinical outcomes (death, recurrence, and metastasis) will be followed up every two years after therapy.

Condition or disease
Primary Liver Cancer

Detailed Description:
Primary liver cancer (PLC) is highly malignant with high mortality which is particularly popular in China. Many factors are believed to associate with the occurrence and prognosis of liver cancer. This longitudinal observational cohort study was designed to investigate factors that influencing the occurrence and long-term survival of patients with primary liver cancer.

Study Type : Observational
Estimated Enrollment : 4000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Factors Influencing the Occurrence and Long-term Survival of Patients With Primary Liver Cancer: A Cohort Study in South China
Actual Study Start Date : January 1, 2013
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer




Primary Outcome Measures :
  1. Time of Death [ Time Frame: Up to 10 years ]
    The exact death time of each participants will be checked in the government medical records system


Secondary Outcome Measures :
  1. Time of recurrence [ Time Frame: From date of diagnosis until the date of cancer recurrence or date of death from any cause, whichever came first, assessed up to 10 years ]
    Time of recurrence will be obtained by telephone interview or medical treatment records

  2. Time of metastasis [ Time Frame: From date of diagnosis until the date of cancer metastasis or date of death from any cause, whichever came first, assessed up to 10 years ]
    Time of metastasis will be obtained by telephone interview or medical treatment records


Biospecimen Retention:   Samples With DNA
Blood and liver tissue were retented during therapy


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients of this study were invited from Sun Yat-sen University Cancer Center as soon as they were diagnosed as primary liver cancer
Criteria

Inclusion Criteria:

  • age 18-80 years
  • consistent with primary liver cancer diagnostic criteria
  • first diagnosis (from diagnosis to admission interval of less than a month)
  • did not do any treatment of liver cancer

Exclusion Criteria:

  • refused to participate in this study
  • suffering from more than two kinds of primary tumors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03297255


Contacts
Contact: Zhu Huilian, Professor +86 20 87331811 zhuhl@mail.sysu.edu.cn
Contact: Fang Aiping 020-87335875 ext 504 fangaip@mail.sysu.edu.cn

Locations
China, Guangdong
Sun Yat-sen University Cancer Center Recruiting
Guangzhou, Guangdong, China, 510000
Contact: Chen Minshan, Professor    +86 20 87343117    chenmsh@sysucc.org.cn   
Sponsors and Collaborators
Huilian Zhu
Investigators
Study Chair: Zhu Huilian, Professor Sun Yat-sen University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Huilian Zhu, Professor, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT03297255     History of Changes
Other Study ID Numbers: SYS-2013
First Posted: September 29, 2017    Key Record Dates
Last Update Posted: September 29, 2017
Last Verified: September 2017

Keywords provided by Huilian Zhu, Sun Yat-sen University:
Primary Liver Cancer; Cohort Study

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Liver Diseases